KLN Logistics Group Limited (KLN) announce that its healthcare subsidiary, KLN Medical Limited (KLN Medical), is now the full-line distributor for APT Medical Inc.'s (APT Medical) coronary intervention products in Hong Kong.

KLN Medical will promote and distribute APT Medical's full coronary intervention portfolio while providing clinical application training, after-sales support and logistics services.

KLN said this collaboration aims to strengthen support for medical professionals and patients and advance the adoption of percutaneous coronary intervention technologies in Hong Kong.

APT Medical offers a portfolio of interventional cardiology products, encompassing key devices such as angiography triads, guiding catheters, percutaneous transluminal coronary angioplasty (PTCA) guidewires, microcatheters, extension catheters, and PTCA balloons.

These products provide patency and operational stability, meeting the demands of both routine and complex percutaneous coronary interventions.

Leveraging KLN’s existing medical logistics network, the products will be distributed to major public and private hospitals across Hong Kong. KLN Medical, which handles medical device logistics, cold‑chain transport, warehousing and inventory management, will support healthcare providers with day‑to‑day supply chain needs.

Samuel Lau, managing director - Integrated Logistics of KLN, said, "We are honoured to partner with APT Medical to offer more options to Hong Kong healthcare institutions and patients through cost-effective, reliable and advanced treatment solutions. With our flexible logistics solutions and commitment to service excellence, we will support the long-term development of the interventional cardiology device market in Hong Kong."

Fangyuan Liu, deputy general manager of APT Medical, said, "As a leading manufacturer and supplier in the interventional cardiology device sector, we are delighted to establish the partnership with KLN Medical. Leveraging KLN's extensive local experience and robust logistics capabilities in the Hong Kong market, we are confident in enabling more healthcare institutions and patients to benefit from our advanced, reliable and cost-effective coronary intervention solutions."